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Abstract
Aims/hypothesis Pancreatic islet microendothelium exhibits
unique features in interdependent relationship with beta
cells. Gastrointestinal products of the ghrelin gene, acylated
ghrelin (AG), unacylated ghrelin (UAG) and obestatin (Ob),
and the incretin, glucagon-like peptide-1 (GLP-1), prevent
apoptosis of pancreatic beta cells. We investigated whether
the ghrelin gene products and the GLP-1 receptor agonist
exendin-4 (Ex-4) display survival effects in human pancreatic
islet microendothelial cells (MECs) exposed to chronic
hyperglycaemia.
Methods Islet MECs were cultured in high glucose concen-
tration and treated with AG, UAG, Ob or Ex-4. Apoptosis
was assessed by DNA fragmentation, Hoechst staining of
the nuclei and caspase-3 activity. Western blot analyses and
pharmacological inhibition of protein kinase B (Akt) and
extracellular signal-related kinase (ERK)1/2 pathways, detec-
tion of intracellular cAMP levels and blockade of adenylyl
cyclase (AC)/cAMP/protein kinase A (PKA) signalling were
performed. Levels of NO, IL-1β and vascular endothelial
growth factor (VEGF)-A in cell culture supernatant fractions
were measured.
Results Islet MECs express the ghrelin receptor GHS-R1A
as well as GLP-1R. Treatment with AG, UAG, Ob and Ex-4
promoted cell survival and significantly inhibited glucose-
induced apoptosis, through activation of PI3K/Akt, ERK1/2
phosphorylation and intracellular cAMP increase. More-
over, peptides upregulated B cell lymphoma 2 (BCL-2)
and downregulated BCL-2-associated X protein (BAX)
and CD40 ligand (CD40L) production, and significantly
reduced the secretion of NO, IL-1β and VEGF-A.
Conclusions/interpretation Theghrelingene-derivedpeptides
and Ex-4 exert cytoprotective effects in islet MECs. The anti-
apoptotic effects involve phosphoinositide 3-kinase (PI3K)/
Akt, ERK1/2 and cAMP/PKA pathways. These peptides could
therefore represent a potential tool to improve islet vascularisa-
tion and, indirectly, islet cell function.
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Introduction
Despite the evidence of some turnover in adult humans and
the apparent capacity of endocrine pancreatic beta cells to
regenerate throughout life, patients with type 1, as well as
type 2, diabetes have a substantial deficit in beta cell mass.
Concomitant with the immune-mediated beta cell destruction,
additional impairments in insulin secretion and beta cell regen-
eration have been proposed in type 1 diabetes. Likewise, type 2
diabetes is accompanied by beta cell apoptosis and failure of
beta cell mass to expand adequately in response to rising
secretory demand [1]. Therefore, identification of molecules
promoting both beta cell survival and function, or regulating
pancreatic gene expression, would help in understanding
the pathophysiology of diabetic disease and to develop new
therapeutic strategies to maintain or restore beta cell mass.
Within this context, recent studies indicate that newly
described gastrointestinal peptides may stimulate prolifera-
tion and prevent apoptosis of pancreatic beta cells. These
peptides include the ghrelin gene products, acylated ghrelin
(AG), unacylated ghrelin (UAG) and the recently identified
peptide, obestatin (Ob). The ghrelin system appears to have
a paracrine/autocrine role in the regulation of hormonal
secretion and islet growth and differentiation in fetal life
[2, 3]. A reciprocal relationship exists between AG and
insulin, suggesting that AG negatively regulates glucose
homeostasis, whereas UAG counteracts the metabolic activ-
ities of AG [4]. Further, the ghrelin isoforms may have a role
in regulating beta cell fate and function, in both physiological
and pathological conditions [5]. The actions of the 23-amino-
acid amidated peptide Ob, initially described as a physiological
opponent of ghrelin, are still mainly unknown [6]. Ob has been
shown to promote beta cell survival, activate signalling path-
ways and induce expression of genes that regulate beta cell
growth, differentiation, insulin synthesis and glucose metabo-
lism [7]. The incretin glucagon-like peptide-1 (GLP-1), the
major gastrointestinal product of proglucagon processing, has
been shown to exert trophic effects on beta cells [8]. GLP-1
stimulates beta cell proliferation, enhances differentiation of
new beta cells from progenitors and inhibits beta cell apoptosis.
GLP-1 receptors are abundantly expressed in many cell types
other than pancreatic islet cells, indicating a role wider than
expected [9].
In their broad range of biological actions, the ghrelin
gene products, as well as GLP-1, feature a variety of cardio-
vascular activities, and share protective effects on cardio-
myocytes and endothelial cells [9–13]. This also renders
these peptides of interest at the microvascular level, which
is endowed with a remarkable heterogeneity of endothelial
phenotype and function [14, 15]. Within the pancreatic
islets, the existence of an endothelial–endocrine axis from
fetal to adult life is well established, and the dense islet
capillary network plays an integral role in a number of islet
functions [16–19]. These functions include insulin gene
expression, optimised beta cell secretory function and blood
glucose regulation, mediated by growth factors, collagen IV
or other basement membrane components [14, 20]. The islet
microcirculation appears to participate in sensing the envi-
ronment and generating signals to induce the growth of the
islets in response to physiological stimuli, such as insulin
resistance or pregnancy [21]. Indeed, increased islet vascu-
lature has been observed in association with expanded islet
mass, and disrupted islet vascular architecture and perfusion
are pathological hallmarks in animal models of diabetes
[22–24]. Moreover, a diabetic milieu induces relevant alter-
ations in islet endothelial cells, leading to apoptosis and NO
and cytokine production [25–27]. At present, no data are
available on the effects of gastrointestinal peptides in islet
endothelium.
The aim of the present study was to evaluate whether AG,
UAG, Ob and the GLP-1R agonist exendin-4 (Ex-4) exert
cytoprotective effects in human islet endothelium. We investi-
gated the potential anti-apoptotic and survival actions of these
peptides in human islet endothelial cells exposed to hyper-
glycaemia and the underlying signalling pathways involved.
Methods
Cell culture conditions Primary islet microendothelial cells
(MECs) were isolated from human islets discarded from
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technique [28]. The immortalised cell line was prepared using
human islets obtained from an organ donor and prepared
in the Cell Isolation Unit at King’s College Hospital
[29]; these studies were approved by the local Ethical
Review Committee. Primary islet MECs were positively
selected using anti-CD105 immunomagnetic beads, purified,
cultured onto endothelial cell attachment factor (Sigma
Aldrich, Milan, Italy) in complete endothelial basal medium
(EBM; Clonetics, San Diego, CA, USA) and character-
ised [30] (see the electronic supplementary material [ESM]).
In high glucose conditions, the medium was adjusted to
28mmol/lglucose(Sigma)[25].Experimentswereconducted
in parallel with physiological (5.6 mmol/l) concentration of
glucose. Because of the need for a long-term culture in high
glucose conditions, the SV40-immortalised human cell line,
established from purified islet MECs, was used [29].
Cell survival and proliferation were assessed by trypan blue
exclusion cell count and by measuring DNA synthesis by the
5-bromo-2′-deoxyuridine (BrdU) incorporation immunoassay
(Cell Proliferation ELISA, BrdU assay; Roche Diagnostics,
Mannheim, Germany). Cell viability was assessed by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay [31]. Five separate experiments in triplicate, at
different time points and with different conditions, were
performed.
In experimental conditions evaluating the effects of AG,
UAG, Ob and Ex-4, cells were incubated with 100 μg/ml
oxidised LDL (oxLDL) for 24 h at 37°C, as a known pro-
apoptotic stimulus [25]. To evaluate the effects of AG, UAG,
Ob and Ex-4 on cell proliferation, survival and apoptosis,
induced by high glucose or oxLDL, as well as the effects on
protein kinase B (Akt), extracellular signal-related kinase (ERK)
1/2 and cAMP/protein kinase A (PKA) pathways, islet MECs
were incubated with increasing doses of AG, UAG, Ob or Ex-4
(10–100 nmol/l; Phoenix Pharmaceuticals, CA, USA), on the
basis of previous reports [7, 31]. Two different conditions were
assayed: peptides were given daily or added overnight before
cell collection. Peptide 14-1 (GSSFLSPEHQRVQQ), the
inverse sequence of UAG fragment 1–14 (Tib MolBiol, Genoa,
Italy) was used as the control peptide. The effects of peptides on
cell survival and proliferation were also assessed in human
umbilical vein-derived endothelial cells (HUVECs).
To assess the secretion of vascular endothelial growth
factor (VEGF)-A and to dissect the distinct contribution to
its secretion of islet endothelium and beta cells, human islet
MECs and a rat glucose-sensitive clonal beta cell line, INS-
1E, were used and cultured as described [31].
Receptor expression Total RNAwas extracted using RNeasy
Minispincolumnsandreversetranscribed(2μg)accordingto
standard protocols using avian myeloblastosis virus reverse
transcriptase and oligo(dT). GHSR1A, GLP1R and GPR39
mRNA expression were assessed by standard PCR, as
described previously [7, 31]. Quantitative real-time PCR
was also performed (see the ESM).
To assess whether the effects of AG were mediated by the
GHS-R1A receptor, cells were incubated with AG in the
presenceof10nmol/lof D-[Lys3]-GHRP-6(PhoenixPharma-
ceuticals), selective antagonist of the cognate AG receptor.
At the protein level, cell surface expression of GHS-R1A
and GPL-1R was assessed by immunofluorescence (IF) and
confocalanalysis;IFstudies were alsoperformedoncryostatic
sections of pancreas tissue (ESM).
Carboxytetramethylrhodamine (TAMRA)-Ob, a fluorescent
Ob derivative (Inbios, Naples, Italy) was synthesised and used
as a probe for Ob binding sites; binding was performed as
described [13] at 4°C and 37°C. 5(6)-TAMRA was used as
negative control.
Detection of apoptosis Apoptosis was evaluated in time
course experiments, at 3–6 days intervals, by a photometric
enzyme immunoassay measuring mono- and oligonucleo-
somes in the cytoplasmic fraction of cell lysates, as an index
of DNA fragmentation (Cell Death Detection ELISA
PLUS,
Roche). Further, islet MECs were also subjected to Hoechst
33258 assay analysis, as described previously [31], and
activation of the caspase family was assessed using the
caspase-3 Colorimetric Activity Assay kit (Chemicon Inter-
national, Temecula, CA, USA). Three separate experiments,
in triplicate, at different time points during different culture
conditions, were performed.
Western blot analyses and intracellular cAMP levels Islet
MECs, subjected to different experimental conditions, were
lysed at 4°C for 30 min in lysis buffer [20]. Samples were
centrifuged, normalised to 50 μg/sample in 20 μl, resolved
by 8% SDS-polyacrylamide gel electrophoresis under reduc-
ing conditions and transferred to nitrocellulose. Membranes
were blocked and incubated with one of the specific antibodies
(mouse monoclonal anti-phosphorylated Akt (p-Akt) or anti-
Akt, or anti-phosphorylated ERK (p-ERK) or anti-ERK, Cell
Signaling Technology, Beverly, MA, USA) overnight at
4°C [25, 31]. Further, MECs were incubated with 100 μmol/
l 3-isobutyl-1-methylxanthine and cAMP was measured from
lysates using the Direct Cyclic AMP EIA kit (Assay Designs,
Milan, Italy), according to the manufacturer’s instructions.
In experiments on the pharmacological inhibition of
phosphoinositide 3-kinase (PI3K), ERK1/2, adenylyl cyclase
(AC) or PKA, islet MECs were treated 1 h before AG, UAG
or Ob treatment with two unrelated PI3K pharmacological
inhibitors, wortmannin (0.1 μmol/l) and LY294002
(10 μmol/l), or an ERK inhibitor, PD98059 (50 μmol/l), an
AC inhibitor, MDL12330A (100 nmol/l), or a PKA inhibitor,
KT5720 (5 μmol/l). Three experiments were performed for
each condition.
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CD40, anti-CD40L, anti-BAX and anti-BCL-2 antibodies
(SantaCruzBiotechnology,Heidelberg,Germany;1:200).Blots
were probed with peroxidase-conjugated goat anti-mouse IgG
(1:5,000; Pierce, Rockford, IL, USA) or peroxidase-conjugated
goat anti-rabbit IgG (Amersham, Little Chalfont, UK)
for 1 h at room temperature and developed with chemilumi-
nescence reagents (ECL; Amersham, Milan, Italy). Three
separate experiments, in duplicate, for each condition, were
performed. Equal protein loading was confirmed by β-actin
production.
The level of CD40L was also evaluated by flow cyto-
metric analysis using CellQuest software (BD Biosciences,
Milan, Italy) [32], in the presence of interleukin (IL)-1β
(10 ng/ml) and TNF-α (50 ng/ml) for 24 h.
IL-1β, NO and VEGF-A detection Cell culture supernatant
fractions were collected before each subculture and medium
exchange and stored at −80°C. IL-1β was measured by
quantitative sandwich enzyme immunoassay (R&D Systems,
Abingdon, UK), according to the manufacturer’s instructions.
NO was determined as nitrite concentration in supernatant
fractions by diazotisation reaction, using NaNO2 as standard
[25]. VEGF-A levels in supernatant fractions of islet MECs
and INS-1E beta cells were detected by human and rat
(respectively) quantitative sandwich enzyme immunoassay
(R&D, Milan, Italy).
Statistical analysis BrdU incorporation, MTT assay, levels
of apoptosis (i.e. optical density for DNA fragmentation),
levels of p-Akt/Akt, p-ERK1/2/ERK1/2, cAMP, IL-1β,N O
and VEGF-A in different culture conditions were compared
using the Mann–Whitney U test. Data were analysed
using SPSS statistical package (SPSS, Chicago, IL,
USA), and p values less than 0.05 were considered
significant. Because of the batch-to-batch and interassay
variations, in some experiments data are represented as per-
centages of variation (mean±SD) of the results obtained in
5.6 mmol/l glucose conditions within each experiment, unless
otherwise stated.
Results
Expression of receptors for AG, Ob and Ex-4 on islet
MECs PCR analyses showed that islet MECs express the
genes encoding the AG receptor, GHSR1A, and the GLP1
receptor, GLP1R, but not GPR39, which encodes one of
the potential Ob receptors (Fig. 1a). The expression was
quantified by real-time PCR (Fig. 1b).
Immunofluorescence studies detected GHS-R1A and
GLP-1R protein expression on islet MECs. These studies
detected labelled Ob binding to islet MECs, which was
reduced by unlabelled Ob. Ob appeared localised mainly
on the cell surface at 4°C, while the majority was
internalised at 37°C (Fig. 1c). GHS-R1A and GLP-1R
proteins were also expressed on sections of human
pancreatic islets. Co-localisation with CD31 indicated the
expression of GHS-R1A and GLP-1R on endothelial cells
lining islet vessels (Fig. 1d).
AG, UAG, Ob and Ex-4 inhibit the effects of high glucose on
islet MEC survival and apoptosis Under conditions of
chronic hyperglycaemia, survival and proliferation of islet
MECs progressively decreased and apoptosis increased,
compared with normoglycaemia (p<0.05; Figs 2a,b, 3a).
Under this condition, the exposure of islet MECs to
10 nmol/l AG, UAG, Ob or Ex-4 promoted cell survival
and proliferation. After a 1 week culture in high glucose, the
number of viable cells, by trypan blue exclusion, was reduced
by 33±11% (n05) compared with cells cultured in physio-
logical glucose concentration. Peptide treatment increased the
viable cell number by 36±15% (AG), 31±25% (UAG), 38±
16% (Ob) and 58±15% (Ex-4; n05) compared with cells
cultured in high glucose without peptides (p<0.05 for AG,
Ob and Ex-4, p00.1 for UAG).
Cell survival by MTT assay was significantly enhanced
as early as 2 days following treatment, reaching an increase
Fig. 1 Expression of GLP1R, GHSR1A and GPR39 and Ob binding.
a Conventional PCR analysis of GLP1R, GHSR1A and GPR39 and of
ACTB mRNA expression in islet MECs (lanes 2, 5, 8 and 11). M, 100-
bp ladder; omission of cDNA in the PCR mixture was used as a
negative control (lanes 1, 4, 7 and 10) and pituitary cells were used
as a positive control (3, 6, 9, 12). Omission in the PCR mixture of
reverse transcriptase enzyme during retrotranscription was also used as
a negative control, providing negative results. b Islet MEC mRNA
levels of GHSR1A and GLP1R determined by real-time PCR. Results
were normalised to an 18S rRNA transcript, and expressed as fold
variation compared with brain gene expression (2ΔΔCt cycle threshold
[Ct]) (means±SD of three independent experiments). Brain and adi-
pose tissues were used as positive controls. Omission of RNA in the
retrotranscription to cDNA provided background signals below the
threshold line used to calculate the Ct value in the real-time PCR
reaction. GPR39 was not expressed in islet MECs (data not shown).
c Representative confocal immunofluorescence micrographs of islet
MECs, stained with anti-GHS-R1A and anti-GLP-1R antibodies,
showing a diffuse receptor expression in islet MECs (original magni-
fication ×630, nuclei stained in blue with DAPI). Immunofluorescence
analysis of TAMRA-Ob binding to islet MECs, which is reduced by
incubation with unlabelled Ob (competitor). Ctrl, 5(6)-TAMRA.
Ob appears to be localised mainly on the cell surface at 4°C and
internalised in the cytoplasm at 37°C. d Representative immuno-
fluorescence micrographs of pancreatic islets stained with anti-
GHS-R1A and anti-GLP-1R antibodies (detected with Alexa Flu-
or 488 conjugated secondary antibody) (original magnification
×400), and anti-CD31 (detected with Alexa Fluor 594 conjugated
secondary antibody). The merge indicates the association of
GHS-R1A and GLP-1R with vessel endothelial cells. GLP-1R is also
present on endocrine cells. Three different pancreases were examined
with similar results
b
Diabetologia (2012) 55:1058–1070 1061of 80% (AG), 68% (UAG), 80% (Ob) and 84% (Ex-4) after
14 days of high glucose culture (p<0.05 compared with
parallel cultures in high glucose without peptides) (Fig. 2a,
Table 1). Concomitantly, under similar conditions, peptide
treatment increased cell proliferation, reaching a significant
mean increase of 86% (AG), 64% (UAG), 87% (Ob)
and 145% (Ex-4) after 14 days of high glucose culture (p<
0.05 compared with cells cultured in high glucose without
peptides) (Fig. 2b, Table 1).
Peptide treatment also substantially increased HUVEC
survival by 62% (AG), 51% (UAG), 70% (Ob) and 48%
(Ex-4) and proliferation by 19% (AG), 22% (UAG), 28%
(Ob) and 32% (Ex-4) after 14 days of high glucose culture,
although without reaching statistical significance.
Exposure to 10 nmol/l AG, UAG, Ob and Ex-4 signifi-
cantly inhibited apoptosis induced by high glucose and by
100 μg/ml oxLDL. In time course experiments, this effect
was evident from the first 2 days of high glucose culture in
the presence of peptides, progressively reaching a mean
decrease in apoptosis of 84% (AG), 84% (UAG), 82% (Ob)
and 68% (Ex-4) after 14 days of culture (p<0.05 compared
with parallel high glucose cultures without peptides; Fig. 3a,
Fig. 2 Ghrelin peptides and Ex-4 promote cell survival and prolifer-
ation of islet MECs cultured in high glucose. a Cell survival, assessed
by MTT assay, of islet MECs cultured for 2 or 14 days in 28 mmol/l
glucose without peptides (1, black bars) or treated with oxLDL
(1, black bar), compared with parallel cultures in normal glucose
(NG, white bar) or high glucose (HG) cultures of cells treated with
10 nmol/l AG (2, grey bars), UAG (3, grey bars), Ob (4, grey bars) or
Ex-4 (5, crosshatched bars). Scrambled peptide 14-1 (6, white bar) in
the 14 day culture represents the control peptide. Culture with 10 nmol/l
AG and selective antagonist of the GHS-R1A receptor, D-[Lys3]-GHRP-
6( 7 ,w h i t eb a r ) .b Proliferation, assessed as BrdU incorporation, of islet
MECsculturedfor2or14daysin28mmol/lglucosewithoutpeptides(1,
black bars) or treated with oxLDL (1, black bar), compared with parallel
cultures in normal glucose (white bar) or high glucose cultures of cells
treatedwith10nmol/lAG(2,greybars),UAG(3,greybars),Ob (4,grey
bars) or Ex-4 (5, crosshatched bars). Scrambled peptide 14-1 (6, white
bar) at 14 day culture represents the control peptide. Culture with
10 nmol/l AG and selective antagonist of the GHS-R1A receptor,
D-[Lys3]-GHRP-6 (7, white bar). OD, optical density. Data are
expressed as mean±SD of three to five different experiments for each
time or treatment point.*p<0.05 compared with parallel high glucose
cultures without peptides.
†p<0.05 compared with normal glucose
cultures
1062 Diabetologia (2012) 55:1058–1070Table 1). These data were confirmed by the significant inhibi-
tion of caspase-3 activation (Fig. 3b) and by Hoechst staining
of apoptotic nuclei (Fig. 3c). The cytoprotective activities of
AG were abrogated by coincubation with D-[Lys3]-GHRP-6
(Figs. 2a,b,3a), and incubation with peptide 14-1 did not show
any protective effect.
AG, UAG, Ob and Ex-4 promote islet MEC survival through
activation of PI3K/Akt, ERK1/2 and AC/cAMP/PKA signalling
pathways Figure 4 shows that protection against glucose-
induced cell death was accompanied by increased phosphor-
ylation of Akt and ERK1/2. The effect was evident both for
overnight and daily peptide treatment, in 7 day high glucose
culture. The ratio of p-Akt/Akt increased by 62% (AG),
73% (UAG), 155% (Ob) and 188% (Ex-4) in an overnight
treatment regime, and by 56% (AG), 28% (UAG), 140%
(Ob) and 162% (Ex-4) in a daily regime. The increase was
statistically significant only for Ob and Ex-4 (Fig. 4a). The
ratio of p-ERK1/2/ERK1/2 increased by 244% (AG), 279%
(UAG), 311% (Ob) and 305% (Ex-4) in an overnight treat-
ment regime, and by 77% (AG), 81% (UAG), 63% (Ob) and
49% (Ex-4) in a daily regime, with statistical significance
for all peptides (Fig. 4b).
Cultures with specific inhibitors of either PI3K/Akt
(LY294002 and wortmannin) or ERK1/2 (PD98059) signifi-
cantly prevented the cytoprotective effects observed with
peptide treatment (Fig. 5a–c).
Chronic high glucose culture significantly decreased the
islet MEC intracellular levels of cAMP, but this was signif-
icantly restored by daily treatment with AG, UAG, Ob or
Ex-4 (Fig. 4c). Furthermore, cultures with specific inhibitors
of AC (MDL12330A) or PKA (KT5720) prevented the
cytoprotective effects of all three ghrelin gene products
and of Ex-4 (Fig. 5a–c), suggesting that their effects were
at least in part dependent on activation of the AC/cAMP/
PKA signalling pathway.
Consistent with data indicating Ob binding to GLP-1R
[7], competition experiments with exendin-9 (Ex-9), a spe-
cific GLP-1R antagonist, prevented the Ob-induced effects
on cell survival, proliferation and apoptosis in high glucose
conditions (Fig. 6a–c). Ex-9 also significantly abrogated the
effects of Ex-4 (Fig. 6a–c), while coincubation of Ob and
Fig. 3 Ghrelin gene peptides and Ex-4 inhibit the effects of high
glucose and oxLDL on apoptosis in islet MECs. a Apoptosis, assessed
as DNA fragmentation of islet MECs, cultured for 2 or 14 days in
28 mmol/l glucose (HG) without peptides (1, black bars) or treated
with oxLDL (1, black bar), compared with parallel cultures in normal
glucose (NG, white bar) or high glucose cultures of cells treated with
10 nmol/l AG (2, grey bars), UAG (3, grey bars), Ob (4, grey bars) or
Ex-4 (5, crosshatched bars). Scrambled peptide 14-1 (6, white bar) in
the 14 day culture represents the control peptide. Culture with
10 nmol/l AG and a selective antagonist of the GHS-R1A receptor, D-
[Lys3]-GHRP-6(7,whitebar).bAssessmentofcaspase-3 activityinislet
MECs incubated for up to 7 days in normal (white bar) or 28 mmol/l
glucose without peptides (1, black bars) compared with parallel high
glucose cultures of cells treated with 10 nmol/l AG (2, grey bars), UAG
(3, grey bars), Ob (4, grey bars), or Ex-4 (5, crosshatched bars). OD,
optical density. Data are expressed as mean ± SD of three different
experiments for each time or treatment point. *p<0.05 compared with
parallel high glucose cultures without peptides.
†p<0.05 compared with
normal glucose cultures. c Representative micrographsof Hoechst 33258
nuclear immunofluorescence staining (original magnification ×100) of
MECs cultured in normal glucose, or in high glucose, treated with
10 nmol/l AG, UAG, Ob or Ex-4
b
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exerted by the single peptides.
Effects of AG, UAG, Ob and Ex-4 on BCL-2, BAX, and
CD40-CD40L expression Western blot analysis of BCL-2
and BAX in hyperglycaemia-induced apoptosis showed that
a 7 day culture in high glucose decreased the production of
the anti-apoptotic BCL-2 protein and enhanced the produc-
tion of the pro-apoptotic BAX protein in islet MECs
(Fig. 7a, b). These changes were reversed by exposure to
ghrelin gene products or Ex-4, with an increase in BCL-2
levels of 115% (AG), 92% (UAG), 109% (Ob) and 94%
(Ex-4) (Fig. 7a), and a decrease of pro-apoptotic BAX levels
to 46% (AG), 58% (UAG), 43% (Ob) and 45% (Ex-4)
(Fig. 7b), compared with the production in parallel high
glucose cultures without peptides.
Densitometric western blot analysis of the co-stimulatory
CD40–CD40L pathway showed that high glucose upregu-
lates the production of CD40L only. This upregulation was
counteracted by exposure to ghrelin gene products or Ex-4
(Fig. 7c) .C h a n g e si nC D 4 0 Lw e r ec o n f i r m e db yf l o w -
cytometric analysis of islet MECs in hyperglycaemic and
inflammatory milieu without (mean fluorescence intensity
[MFI] 22.6±2.2) or with 10 mmol/l Ob (mean MFI 13.3±
1.5; Fig. 7d).
Effects of AG, UAG, Ob and Ex-4 on levels of NO, IL-1β
and VEGF-A in cell supernatant fractions Mean values for
repeated measurements of IL-1β and of the stable NO
oxidation product, nitrite, were significantly higher in su-
pernatant fractions of high glucose cultures than normal
glucose cultures, and were significantly reduced by treat-
ment with AG, UAG, Ob or Ex-4 (Fig. 8a, b; p<0.01 for IL-
1β and p<0.05 for NO).
In time course experiments, levels of VEGF-A progres-
sively increased in supernatant fractions of both islet endothe-
lial and beta cells in high glucose (p<0.05 compared with
normal glucose for both cell types). The increased secretion
was abrogated bythe treatment withAG, UAG, OborEx-4in
both cell cultures (Fig. 8c, d).
Discussion
The present study shows the ability of the ghrelin gene
products and of the GLP-1 receptor agonist exendin-4 to
inhibit apoptosis of human pancreatic endothelial cells in-
duced by glucose toxicity. Islet MECs constitutively
expressed GHS-R1A and GLP-1R, which may explain the
biological effect of AG and Ex-4. UAG was also shown to
be an active peptide despite acting on an unknown receptor
[5]. Although AG desacylation and binding to the hypothetical
UAG receptor may contribute to AG biological activity, recep-
tor antagonist experiments suggest a direct AG effect, through
GHS-R1A binding. The orphan receptor G-protein coupled
receptor 39 (GPR39), a potential receptor of Ob [33], was not
detected in islet MECs. However, immunofluorescence and
GLP-1R competition studies indicated that Ob binds to GLP-
1R expressed by islet MECs [7]. Expression of GHS-R1A in
islet endothelial cells, together with the established production
of ghrelin within pancreatic islets [3, 34], may sustain the
autocrine/paracrine circuits active between endocrine and
endothelial counterparts within the islet of Langerhans [14].
Sustained and intermittent hyperglycaemia affects endo-
thelial cellular survival and proliferation, including the islet
microendothelium [25]. Several metabolic mechanisms are
involved, including oxidative stress, increased intracellular
Ca
2+, mitochondrial dysfunction, changes in fatty-acid
metabolism and impairedphosphorylation of theproteinkinase
Akt [35]. The Akt signalling cascade plays a pivotal role in
preventing apoptosis in a variety of settings, and has a role in
insulin-mediated glucose transport and pancreatic beta cell
mass and function [36]. In the present study, sustained high
glucose levels impaired ERK1/2 tyrosine phosphorylation as
well, and reduced intracellular cAMP and its targets, the
cAMP-dependent PKA pathways, known to promote cell
growth and to delay apoptosis [37]. The ghrelin gene products,
independently of their acylation, promptly promoted cell
survival and halted the cell proliferation impairment induced
by the metabolic condition. The anti-apoptotic activity was
mediated by tyrosine phosphorylation and activation of PI3K/
Akt and ERK1/2 pathways, and by activation the cAMP/PKA
Table 1 Median and interquartile ranges (Q1/median/Q3) of optical density (OD) for MTT cell survival, BrdU proliferation and DNA
fragmentation apoptosis assays
5.6 mmol/l
glucose
28 mmol/l
glucose
28 mmol/l
glucose+AG
28 mmol/l
glucose+UAG
28 mmol/l
glucose+Ob
28 mmol/l
glucose+Ex-4
MTT assay 0.76/0.82/0.84 0.41/0.43/0.53
† 0.65/0.69/0.73
* 0.6/0.62/0.68
* 0.66/0.71/0.73
* 0.56/0.77/0.82
*
BrdU assay 1.24/1.73/2.04 0.47/0.67/0.73
† 0.95/1.05/1.25
* 0.94/1.02/1.07
* 0.99/1.01/1.19
* 1.1/1.43/1.75
*
DNA fragmentation assay 0.15/0.19/0.23 1.32/1.64/1.68
† 0.11/0.22/0.26
* 0.08/0.16/0.24
* 0.1/0.19/0.22
* 0.21/0.4/0.46
*
Islet MECs were cultured in 5.6 mmol/l glucose or 28 mmol/l glucose for 14 days, without or with ghrelin peptides or Ex-4. Three to five separate
experiments, each in triplicate, were performed for each experimental condition
*p<0.05 vs parallel 28 mmol/l glucose cultures without peptide;
†p<0.05 vs parallel 5.6 mmol/l glucose cultures
1064 Diabetologia (2012) 55:1058–1070signalling pathway, as indicated by cAMP intracellular levels
and by inhibition of AC and of the downstream pathway of
cAMPinvolvingPKA.These multifunctional pathwaystrans-
mit signals that result in prevention of apoptosis or induction
of cell cycle progression, depending on the cell type, and can
cross-regulate one another [37].
The mechanisms underlying apoptosis are regulated by
defined biochemical pathways and involve members of the
BCL-2 family [38]. In the present study, pro-survival BCL-2
protein, which stabilises the mitochondrial membrane and
prevents the release of cytochrome C from the mitochondria
and the activation of caspases, was found to be downregulated
by high glucose. In contrast, the pro-apoptotic member, BAX,
which antagonises BCL-2, was upregulated. These alterations
were counteracted by treatment with AG, UAG and Ob, pro-
viding further insight into the mechanisms of their cytoprotec-
tive effects. Cytoprotective activities, mediated by similar
mechanisms, were shown to be shared by the GLP-1R agonist
Ex-4. GLP-1R is abundantly produced in extra-pancreatic
tissues, including vascular endothelial cells and immune cells.
Beyond its metabolic effects, GLP-1 has been demonstrated to
ameliorate endothelial dysfunction, as well as to be involved in
immunoregulatory processes [9, 39]. Our findings extend its
regenerative actions from beta cells to the islet endothe-
lium and add further interest to GLP-1R agonists, which
not only improve the pathophysiology of the diabetic
state, but may be of interest as an adjunctive therapy in
the setting of immunomodulation/beta cell regeneration
and islet transplantation [40].
High glucose conditions upregulated CD40L production in
islet MECs. Functional CD40L is produced on the vascular
endothelium [41] and contributes to B cell activation, isotype
switching, co-stimulation in T cell mediated immunity and
activation of extravasating monocytes [42], with an impact in
atherosclerosis and in chronic inflammatory and autoimmune
diseases. Blockers of CD40L have been strikingly effective in
animal models of autoimmune diseases, such as systemic lupus
erythematosus and type 1 diabetes [43]. Ghrelin gene products
and Ex-4 were able to downregulate CD40L production in islet
MECs. Together with early and intensive insulin therapy or
combined with immunotherapies, these peptides might decel-
erate the targeting and loss of the remaining beta cell capacity
during autoimmune insulitis. Human and murine studies indi-
cate that, during insulitis, the endothelial cells surrounding the
islets adopt an activated phenotype and are involved in the
regulation of mononuclear cell transmigration and homing in
the islets [44]. In line with our findings, Ex-4 has been recently
shown to inhibit monocyte adhesion to the endothelium and to
regulate inflammation in macrophages via the cAMP/PKA
pathway [9]. It is noteworthy that overproduction of BCL-2
inendothelialcellsdecreasesTcellcytotoxicity,suggestingthat
this protein may also protect endothelial cells from apoptosis
resulting from an immunological insult [45].
Fig. 4 Ghrelin gene peptides and Ex-4 prevent the reduction of Akt
and ERK phosphorylation and intracellular cAMP levels. a Phosphor-
ylation of Akt and the p-Akt/Akt ratio evaluated as densitometric
analysis of western blot bands in islet MECs cultured in normal (NG)
or 28 mmol/l glucose (HG) without peptides for 7 days (1, black bars),
or treated with 10 nmol/l AG (2, grey bars), UAG (3, grey bars), Ob (4,
grey bars) or Ex-4 (5, grey bars) in two regime treatments, 7 days or
12 h. b Phosphorylation of ERK1/2 and the p-ERK/ERK ratio evalu-
ated as densitometric analysis of western blot bands in islet MECs
cultured in normal or 28 mmol/l glucose without peptides for 7 days
(1, black bars) or treated with 10 nmol/l AG (2, grey bars), UAG
(3, grey bars), Ob (4, grey bars) or Ex-4 (5, cross hatched bars) in two
regime treatments, 7 days or 12 h. c Intracellular cAMP levels in islet
MECs cultured in normal glucose or 28 mmol/l glucose without peptides
for 7 days (1, black bar) compared with parallel cultures of cells treated
with 10 nmol/l AG (2, grey bar), UAG (3, grey bar), Ob (4, grey bar) or
Ex-4 (5, crosshatched bar). Data are expressed as mean±SD of three
differentexperiments foreachtime ortreatment point.*p<0.05compared
with parallel high glucose cultures without peptides.
†p<0.05 compared
with normal glucose cultures
Diabetologia (2012) 55:1058–1070 1065Fig. 5 Ghrelin gene peptides and Ex-4 effects are prevented by pharma-
cological inhibition of PI3K/Akt, ERK1/2, AC or PKA on cell survival
and apoptosis of islet MECs cultured in high glucose. a A reduction in
cell survival, assessed by MTT assay, was induced by simultaneous
treatment of islet MECs cultured in 28 mmol/l glucose (HG) for 7 days,
withAG,UAG,Ob,orEx-4(vehicle)andinhibitorsofPI3K(LY294002,
10 μmol/l [Ly] and wortmannin, 0.1 μmol/l [Wort]) or ERK1/2
(PD98059, 50 μmol/l [PD]) or AC (MDL12330A, 100 nmol/l [MDL])
or PKA (KT5720, 5 μmol/l [KT]). The black bar shows high glucose
cultures without peptides. b An increase in apoptosis, assessed as DNA
fragmentation, was induced by simultaneous treatment of islet MECs
cultured in 28 mmol/l glucose for 7 days, with AG, UAG, Ob, or Ex-4
(vehicle) and inhibitors of PI3K (LY294002, 10 μmol/l and wortmannin,
0.1 μmol/l) or ERK1/2 (PD98059, 50 μmol/l) or AC (MDL12330A,
100 nmol/l) or PKA (KT5720, 5 μmol/l). The bar shows high glucose
cultureswithoutpeptides.cAnincreaseincaspase-3activitywasinduced
by simultaneous treatment of islet MECs cultured in 28 mmol/l glucose
for 7 days, with AG, UAG, Ob or Ex-4 (vehicle) and inhibitors of PI3K
(LY294002,10μmol/l and wortmannin, 0.1 μmol/l),ERK1/2(PD98059,
50μmol/l),AC (MDL12330A, 100 nmol/l) or PKA (KT5720, 5 μmol/l).
The black bar shows high glucose cultures without peptides. OD, optical
density. Data are expressed as mean±SD of three different experiments
for each treatment point. *p<0.05comparedwithparallel normalglucose
and high glucose cultures with peptides alone (vehicle). Incubation with
pathwayinhibitorsdidnotsignificantlymodifycellsurvival,apoptosis,or
caspase-3 activity in high glucose cultures without peptides (data not
shown)
1066 Diabetologia (2012) 55:1058–1070Increasing evidence points to an interdependent physical
and functional relationship between islet endothelium and
beta cells, from organogenesis to adult life [14]. Post-natal
beta cell mass is dynamic and can increase in function and
mass for added demand, possibly by microendothelial
inductive signals [20, 21, 46]. Diabetes, in all forms, is charac-
terised by progressive reduction of beta cell function and mass
together with impaired insulin secretion and beta cell regener-
ation. Several mechanisms have been proposed. These include
increased vulnerability to apoptosis induced by inflammatory
cytokines, induction of NO synthase (NOS)-dependent
mechanisms and production of the vasoactive mediator, NO
[1, 25], endothelial cell loss, and vasculature disruption [18,
23,24].NO,whichisincreasedinhyperglycaemicconditions,
has an established direct cytotoxicity in islets and potentially
impairs insulin release [47]. Islet MECs are also a source of
the proinflammatory cytokine IL-1β under hyperglycaemic
conditions, independently of any viral or immune-mediated
process.IL-1βimpairsinsulinreleaseinhumanislets,induces
TNF receptor superfamily, member 6 (FAS) expression en-
abling FAS-mediated apoptosis, and acts as a mediator of
glucotoxicity [27]. In the present study, ghrelin gene products
and Ex-4 significantly reduced the production of NO and IL-
1β, providingan additional mechanism bywhich the peptides
Fig. 7 Production of BCL-2, BAX and CD40L. a Production of BCL-2
evaluated as densitometric analysis of western blot bands in islet MECs
cultured in normal (1, white bar) or 28 mmol/l glucose (2, black bar) for
7 days or treated with 10 nmol/l of AG (3, grey bar), UAG (4, grey bar),
Ob (5, grey bar) or Ex-4 (6, crosshatched bar). b Production of BAX
evaluated as densitometric analysis of western blot bands in islet MECs
cultured in normal (1, white bar) or 28 mmol/l glucose (2, black bar) for
7 days or treated with 10 nmol/l of AG (3, grey bar), UAG (4, grey bar),
Ob (5, grey bar) or Ex-4 (6, crosshatched bar). c Production of CD40L
evaluated as densitometric analysis of western blot bands in islet MECs
cultured in normal (1, white bar) or 28 mmol/l glucose (2, black
bar) for 7 days or treated with 10 nmol/l of AG (3, grey bar), UAG (4,
grey bar), Ob (5, grey bar) or Ex-4 (6, crosshatched bar). OD, optical
density. Data are expressed as mean±SD of three different experiments.
*p<0.05 compared with parallel normal glucose and high glucose
cultures with peptides. d Representative flow-cytometric analysis of
human islet MECs cultured in normal glucose (NG) or in 28 mmol/l
glucose (HG) (7 days) with IL-1β (10 ng/ml) and TNF-α (50 mg/ml) for
24h,stainedforCD40L(darklinehistograms)andcorrespondingisotype
control antibodies (dashed line histograms). Thin line histogram repre-
sents CD40L production in cells treated with 10 nmol/l Ob in high
glucose. Three separate experiments showed similar results
Fig. 6 Effects of the specific GLP-1 antagonist Ex-9 (500 nmol/l).
Effects of Ex-9 treatment on apoptosis (a), assessed as DNA fragmen-
tation, survival (b), assessed by MTT assay, and proliferation (c),
assessed as BrdU incorporation of islet MECs cultured for 7 days in
28 mmol/l glucose (HG) and treated with 10 nmol/l Ob or Ex-4 (grey
bars). Normal glucose (NG, white bars), 28 mmol/l glucose (black
bars). Data are expressed as mean±SD of three different experiments
for each treatment point. *p<0.05 compared with parallel high glucose
cultures without peptides and cultures in the presence of Ex-9
Diabetologia (2012) 55:1058–1070 1067can directly protect beta cells, beyond their effects on islet
vascularisation.
The major vascular endothelial growth factor, VEGF-A,
is responsible for islet vascularisation [16, 17]. Persistent
high glucose enhanced VEGF-A secretion by islet endothelial
and beta cells. Glucose is reported to enhance synthesis of
VEGF-A in cultured islets of Zucker diabetes fatty (ZDF) rats,
a model of type 2 diabetes [24], which show progressive
disruption of vascular endothelium and islet failure. Indeed,
in murine models, hyperglycaemia in the short-term increases
islet capillary blood pressure and perfusion in a glucose-
dependent and reversible pathway [23]. When persistent,
hyperglycaemia, by increasing islet flow and pressure, contrib-
utes to the disruption of islet endothelium. These changes lead
to islet hypoperfusion and failure [18, 24]. In our report, the
cytoprotective effects of ghrelin gene peptides and of Ex-4
were accompanied by abrogation of the glucose-induced
VEGF-A increase. Such an effect has no immediate
explanation. Studies on the angiogenic properties of ghrelin
and GLP-1 are scanty and contradictory [48, 49], reflecting the
heterogeneity of the microendothelium derived from different
organs. However, it is noteworthy that thiazolidinedione pio-
glitazone prevented diabetes in the ZDF rat model [24], by
preventing both the decrease in endothelial cell number and the
endothelial hypertrophy, concomitant with a reduction in the
VEGF-Alevel. Furthermore, renal production of VEGF-A
is consistently upregulated by hyperglycaemia and in exper-
imental and human diabetes. Inhibition of VEGF-A has ben-
eficial effects on diabetes-induced glomerular functional and
structural alterations, indicating a deleterious role for VEGF-
A in the pathophysiology of diabetic nephropathy [50]. Pan-
creatic islets and renal glomeruli share ultrastructural features
[14].
In conclusion, we provide evidence that metabolic stress
is detrimental to islet endothelial cells, which are targets and
effectors of the hyperglycaemic condition. The cytoprotective
Fig. 8 Endothelial IL-1β and NO production, and endothelial and
INS-1E rat beta cell VEGF-A production. a Mean value±SD of IL-1β
in cell free supernatant fractions of islet MECs in normal glucose (NG,
white bar), in 28 mmol/l glucose (HG) (1, black bar), or treated with
10 nmol/l AG (2, grey bar), UAG (3, grey bar), Ob (4, grey bar) or Ex-4
(5, crosshatched bar). b Mean value±SD of NO in cell free supernatant
fractions of islet MECs in normal (white bar), in 28 mmol/l glucose
(1, black bar) or treated with 10 nmol/l AG (2, grey bar), UAG (3, grey
bar), Ob (4, grey bar) or Ex-4 (5, crosshatched bar). c Mean value±SD of
VEGF-Ain cellfreesupernatantfractionsofislet MECsinnormal (white
bar), in 28 mmol/l (1, black bars) glucose, or treated with 10 nmol/l AG
(2, grey bars), UAG (3, grey bars), Ob (4, grey bars) or Ex-4 (5, cross-
hatched bars). d Mean value±SD of VEGF-A in cell free supernatant
fraction of INS-1E rat beta cells in normal (white bar), in 28 mmol/l
glucose (1, black bars),ortreated with 10 nmol/lAG(2, grey bars), UAG
(3, grey bars), Ob (4, grey bars) or Ex-4 (5, crosshatched bars). Data are
expressed as mean±SD of three different experiments for each treatment
or time point. *p<0.05 compared with parallel normal glucose cultures
and high glucose cultures with peptides
1068 Diabetologia (2012) 55:1058–1070effect exerted by ghrelin gene peptides and incretin Ex-4, in
association with their reported regenerative effect on residual
beta cell capacity, renders these peptides an appealing thera-
peutic tool to regulate islet fate in vivo.
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